Q-omics provides the consensus-scored SMCR8 profile across patient tissues and cancer cell-line models. SMCR8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SMCR8 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, SMCR8 RNA expression shows 19,897 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where SMCR8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMCR8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMCR8 survival associations across molecular data types. SMCR8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMCR8 RNA expression–survival associations across cancer types. High SMCR8 expression shows unfavorable associations in LIHC and KICH, but favorable associations in KIRC, SCLC, HNSC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SMCR8 RNA expression.
This table summarizes SMCR8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SMCR8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMCR8 shows lower tumor expression in THCA and COAD and higher tumor expression in HNSC, LIHC, KIRP and CHOL. The HNSC box plot shows higher SMCR8 RNA expression in tumor versus normal tissue (log2 FC = +0.718, t-test p < 0.001).
This table shows molecular features associated with SMCR8 in patient tissues and cancer cell lines. In patient samples, SMCR8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMCR8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
